Multi-dimensional nullgram profiling and Cyberpatient-in-the-loop testing enable rational design of closed-loop cell-based therapies, revealing that dimeric v2-buffer controller topology overcomes high-setpoint limitations of monomeric controllers through elimination of dominant-negative splice products, thereby achieving robust autonomous regulation of TNF-α and downstream inflammatory cytokines in primary human immune cells.

Adaptive, closed-loop control of cellular behavior is essential for next-generation therapies, yet most current treatments operate in an open-loop manner and lack robustness to patient variability and disease dynamics. Here, we establish a controltheoretic platform for rational engineering of closed-loop cell-based therapies that achieve precise and robust regulation. First, we introduce multi-dimensional nullgram profiling, a high-throughput approach that enables quantitative prediction and design of advanced genetic controllers in human cells across circuit topologies and parameter regimes in a single experiment. To evaluate dynamic therapeutic behavior, we next develop Cyberpatient-in-the-loop, an optogenetic digital twin platform that interfaces engineered mammalian cells with computational disease models, enabling systematic testing of closed-loop performance under realistic perturbations. Finally, we leverage these approaches to implement integral feedback cell therapies that sense inflammatory signals and autonomously regulate cytokine levels in primary immune cell cultures. Together, these results establish a general paradigm for engineering cellbased control systems and provide a foundation for next-generation cell therapies.